Online inquiry

IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15961MR)

This product GTTS-WQ15961MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15961MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ296MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ6232MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ417MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ5994MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ14907MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ15572MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ1283MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ15580MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW